Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):331-6. doi: 10.1016/j.clinre.2013.10.012. Epub 2013 Dec 30.

Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg-negative acute-on-chronic liver failure.

Author information

  • 1Department of Infectious Diseases, Third Affiliated Hospital, Sun Yat-Sen University, No 600# Tianhe Road, Guangzhou 510630, P.R. China. Electronic address: yankee2@21.com.
  • 2Department of Infectious Diseases, Third Affiliated Hospital, Sun Yat-Sen University, No 600# Tianhe Road, Guangzhou 510630, P.R. China.

Abstract

BACKGROUND AND OBJECTIVE:

Few data are available about the predictability of HBsAg quantification to nucleos(t)ide analogues treatment in acute-on-chronic liver failure (ACLF). The aim of this study was to investigate HBsAg level combined with the model for end-stage liver disease (MELD) score for predicting prognosis to lamivudine monotherapy in HBeAg-negative ACLF.

METHODS:

Fifty-seven nucleoside-naïve patients with HBeAg-negative ACLF were treated with 100mg of lamivudine daily. Serum levels of HBsAg, HBV DNA and biochemical items were detected at baseline, before death (patients died within 3months) or month 3 meanwhile MELD score was calculated. Dynamic of these items and 3-month mortality were analyzed.

RESULTS:

HBV DNA level significantly decreased while HBsAg level did not after treatment. Twenty-six patients died within 3months and the others survived. Regardless pre- or post-treatment, HBsAg level of survival group was significantly higher than that of dead group meanwhile MELD scores of the former were significantly lower than those of the latter (all P<0.05). Post-treatment MELD scores of 32 patients with pretreatment HBsAg levels above 4000 COI were significantly lower than those of 25 patients below to it (t=-2.116, P=0.044) and the 3-month mortality of the formers was significantly lower than that of the latter (34.3% [11/32] vs 64.0% [16/25], χ(2)=4.941, P=0.026).

CONCLUSIONS:

In HBeAg-negative ACLF, patient with higher pretreatment HBsAg levels and early decrease in MELD score has lower 3-month mortality than one without it during lamivudine monotherapy.

Copyright © 2013 Elsevier Masson SAS. All rights reserved.

PMID:
24388342
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk